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ABSTRACT
Objectives: Emergency endovascular aneurysm repair
(eEVAR) may improve outcomes for patients with
ruptured abdominal aortic aneurysm (RAAA). The
study aim was to compare the outcomes for eEVAR
with conventional open surgical repair for the treatment
of RAAA.
Setting: A systematic review of relevant publications
was performed. Randomised controlled trials (RCTs)
comparing eEVAR with open surgical repair for RAAA
were included.
Participants: 3 RCTs were included, with a total of
761 patients with RAAA.
Interventions: Meta-analysis was performed with
fixed-effects models with ORs and 95% CIs for
dichotomous data and mean differences with 95% CIs
for continuous data.
Primary and secondary outcome measures:
Primary outcome was short-term mortality. Secondary
outcome measures included aneurysm-specific and
general complication rates, quality of life and economic
analysis.
Results: Overall risk of bias was low. There was no
difference between the 2 interventions on 30-day (or
in-hospital) mortality, OR 0.91 (95% CI 0.67 to 1.22;
p=0.52). 30-day complications included myocardial
infarction, stroke, composite cardiac complications,
renal complications, severe bowel ischaemia, spinal
cord ischaemia, reoperation, amputation and
respiratory failure. Reporting was incomplete, and no
robust conclusion was drawn. For complication
outcomes that did include at least 2 studies in the
meta-analysis, there was no clear evidence to support
a difference between eEVAR and open repair. Longer
term outcomes and cost per patient were evaluated in
only a single study, thus precluding definite
conclusions.
Conclusions: Outcomes between eEVAR and open
repair, specifically 30-day mortality, are similar.
However, further high-quality trials are required, as the
paucity of data currently limits the conclusions.
BACKGROUND
Abdominal aortic aneurysm (AAA) affects
between 1.2% and 7.6% of the population
over 50 years of age in the UK. There has
been recent decline in prevalence to about
2%. This is independent of participant selec-
tion criteria and reﬂects better cardiovascu-
lar risk proﬁling and management in the
overall population.1 2 Unfortunately, many
aneurysms ﬁrst present as a rupture resulting
in death in the majority of those affected.
The high mortality rate from ruptured AAA
(RAAA) is well recognised. Clinicians have
been reticent to apply scoring systems rigidly
as to do so would condemn many to certain
death.3–5 Patients who undergo successful
open repair of RAAA enjoy a postoperative
quality of life similar to the ‘normal popula-
tion’.6 7 The risk of aneurysm rupture is pro-
portional to aneurysm size, with aneurysms
measuring less than 5.4 cm having an annual
rupture rate of approximately 1% whereas
those greater than 7.0 cm in diameter have
an annual rupture rate of 32.5%.8 9 Currently,
rupture leads to death in over 80% of those
affected, including 30–65% of those who
receive conventional open surgical repair and
is responsible for 2.1% of all deaths in men
over 65 years.8 10–12 These ﬁndings contrast
with the signiﬁcantly better outcome if con-
ventional open surgical repair of the AAA is
planned before rupture can occur.
Strengths and limitations of this study
▪ This is the first study to do a meta-analysis of
the three major randomised controlled trials
comparing endovascular and open repair of
abdominal aortic aneurysms.
▪ The major finding is that there is no difference
seen between operative modalities for ruptured
aneurysm repair in terms of morbidity or
mortality.
▪ The quality of the study is reduced by the lack of
complete reporting in the trials.
▪ Long-term outcome data would enhance the
results of the meta-analysis and is still awaited.
▪ Robust conclusions are difficult to draw due to
paucity of data, but one modality should not be
favoured over another based on current research.
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Historically, open surgical repair was the only effective
treatment for AAA. This major operation carries signiﬁ-
cant morbidity and mortality, due to the combined
effects of surgical exposure, haemorrhage and aortic
clamping with related lower torso ischaemia-reperfusion
injury. However, with improved patient selection and
perioperative care, some specialist centres are reporting
mortality rates of less than 2% and surgeons in non-
specialist units achieving mortality rates of 5–8%.8–10
However, in the past two decades, this treatment has
been challenged by endovascular aneurysm repair
(EVAR). Signiﬁcant advancements in commercial stent
design, delivery and implantation technique have made
this a valuable alternative to open repair in selected suit-
able cases.13–15 Its use in elective cases has reduced early
postoperative morbidity and mortality.16 17 Its minimally
invasive nature allows it to be performed under regional
or even local anaesthesia, rather than general anaesthe-
sia. This allows repair in patients with signiﬁcant con-
comitant medical disease who may otherwise have been
considered unﬁt for surgery.10 18 Two recent large pro-
spective randomised controlled trials (RCTs) have shown
reduced early complications and mortality with
EVAR.16 17 However, while elective endovascular repair
clearly has a role, these trials reinforce the knowledge
that open repair will remain the treatment for a large
proportion of patients whose AAA is unsuitable on ana-
tomical grounds for EVAR.16 19 20 In addition, long-term
results from the EVAR 1 trial should add caution, with
later ruptures in the EVAR group, and no long-term dif-
ference in the all-cause mortality.21
Rupture of an AAA (RAAA) is a catastrophic event,
with up to 80% mortality.22 23 RAAA exposes the patients
to the combined injury of a period of haemorrhagic
shock and lower torso ischaemia followed by a reperfu-
sion injury on successful revascularisation. This ‘two hit’
mechanism of injury initiates a systemic inﬂammatory
response syndrome, leading to a multiple organ dysfunc-
tion syndrome (MODS).24 MODS is the primary cause
of 70% of such deaths and a contributory cause of the
remainder.25 26 The multiorgan failure, despite intensive
care support, once established leads to death in over
70% of cases.25 27 EVAR, especially under local anaesthe-
sia, reduces the physiological insult to the body as com-
pared with conventional open surgical repair.28 29
Emergency EVAR (eEVAR) appears to offer a feasible
alternative to conventional open repair in selected
patients.29 30 Emergency cases were repaired with an aor-
touniiliac stent graft, contralateral occluder and fem-fem
crossover in the initial years, due to increased speed of
Figure 1 PRISMA flow chart of
literature selection. TSC, Trials
Search Co-ordinator.
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achieving a seal and haemodynamic stability. However,
the use of bifurcated stent graft is routine for ruptured
AAA. Early reports have suggested a trend towards
reduction in perioperative morbidity and mortality in
selected patients. Indeed evidence is emerging that the
inﬂammatory response to RAAA repair and the asso-
ciated organ dysfunction is attenuated by eEVAR com-
pared with open repair.31 32
The purpose of this review was to assess the available
evidence to support the use of eEVAR to treat RAAA.
The advantages and disadvantages of eEVAR for patients
with RAAA was determined by the effect on short-term
mortality, major complication rates, aneurysm exclusion
and late complications when compared with patients
who have had conventional open repair of RAAA. The
results of this review have been published as a Cochrane
review, which was an update of the initial study.33 34
METHODS
Only prospective RCTs comparing eEVAR with conven-
tional open surgical repair were considered eligible for
inclusion. Within the studies, all patients in whom a
RAAA has been clinically diagnosed by CT, angiography,
MR angiography or objective acute symptoms suggestive
of impending rupture of the aneurysm to warrant inclu-
sion. All types of endovascular devices were considered
in comparison with conventional open surgical treat-
ment for patients considered ﬁt for surgery.
The primary outcome for the study was the short-term
morality (30-day, or in-hospital mortality). Secondary
outcomes included:
▸ Aneurysm exclusion, or further extravasation beyond
the sac on follow-up imaging 30 days after the
procedure;
▸ Major complications, such as open conversion, haemor-
rhage, myocardial infarction, stroke, renal failure (20%
rise in creatinine levels), respiratory failure (require-
ment for postoperative mechanical ventilation), pneu-
monia, bowel ischaemia, lower limb ischaemia;
▸ Minor complications, such as catheter site haema-
toma, wound infection;
▸ Long-term complications and mortality; reinterven-
tion rates for problems related to the RAAA or its
treatment will be sought where possible, as will cause
of death, with or without reintervention, that is,
device related;
▸ Quality of life (standardised questionnaires);
▸ Economic analysis (cost per patient).
SEARCH METHODS
For this update, the Cochrane Peripheral Vascular
Diseases Group Trials Search Co-ordinator (TSC)
searched the Specialised Register (last searched
February 2014) and the Cochrane Central Register of
Controlled Trials (CENTRAL) 2014, Issue 2, part of The
Cochrane Library.35 The Specialised Register is main-
tained by the TSC and is constructed from weekly
electronic searches of MEDLINE, EMBASE, CINAHL,
AMED and through hand searching relevant journals.
The full list of the databases, journals and conference
proceedings which have been searched, as well as the
search strategies used are described in the Specialised
Register section of the Cochrane Peripheral Vascular
Diseases Group module in The Cochrane Library.35 36
References of relevant studies were reviewed for other
pertinent publications.
Data collection and extraction
Two authors (SAB and RB) independently reviewed the
studies identiﬁed by the search for their relevance using
the selection criteria. Disagreements were resolved
through discussion. Two review authors (SAB and RB)
independently extracted data for each included study.
Table 1 The string search performed of the terms in the
literature
#1 MeSH descriptor: [Ednovascular
Procedures] explode all trees
6017
#2 MeSH descriptor: [Stents] explode all trees 3314
#3 MeSH descriptor: [Vascular Surgical
Procedures] this term only
652
#4 Endovasc*:ti,ab,kw 941
#5 Endostent*:ti,ab,kw 1
#6 Endograft* 81
#7 EVRAR:ti,ab,kw 1
#8 (EVAR or REVAR):ti,ab,kw 74
#9 (Palmaz):ti,ab,kw 91
#10 *stent* or graft* 54 489
#11 Palmaz:ti,ab,kw 91
#12 Viabahn or Nitinol or Hemobahn or Intracoil
or Tantalum or powerlink or excluder or
talent or aorfix or endologix or anaconda:ti,
ab,kw
207
#13 Zenith or Dynalink or Hemobahn or
Luminex or Memotherm or Wallstent:ti,ab,
kw
128
#14 MeSH descriptor: [Blood Vessel Prosthesis]
explode all terms
452
#15 MeSH descriptor: {Blood Vessel Prosthesis
Implantation] this term only
508
#16 Endoprosthesis:ti,ab,kw 142
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
or #9 or #10 or #11 or #12 or #13 or #14 or
#15 or #16
59 170
#18 MeSH descriptor: [Aneurysm, Ruptured]
explode all terms
201
#19 MeSH descriptor: [Aneurysm, Dissecting]
this term only
73
#20 (aneurysm* or abdom* or thoracoabdom* or
thorac-abdom* or aort*) near (ruptur* or
tear or bleed* or trauma)
1195
#21 MeSH descriptor: [Aorta] explode all trees
and with qualifier(s): [Surgery—SU]
317
#22 RAAA 12
#23 #18 or #19 or #20 or #21 or #22 1545
#24 #17 and #23 in Trials 309
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Table 2 The details of the Hinchliffe study
Methods Study type: single-centre, randomised controlled trial, open label, intention-to-treat
Study aim: to test the hypothesis that EVAR can reduce the perioperative mortality of
ruptured AAA, compared with open repair
Country: England
Setting: hospital
Participants Number randomised: total n=32 (eEVAR n=15; open repair n=17)
Age (median years (IQR)): eEVAR=74 years (68.8–79.5); open repair=80 years (73. 8–83.8)
Gender (M/F): eEVAR=11/4; open repair=13/4
Inclusion criteria: all patients admitted with clinically suspected or radiologically confirmed
rupture of an infrarenal abdominal aortic aneurysm that, in the opinion of the duty
consultant vascular surgeon would normally be treated with open repair
Exclusion criteria: no endovascular team available; full selection of emergency stent grafts
not available; age <50 years; inability to give verbal or written consent; unconscious patient;
allergy to radiological contrast, stainless steel or polyester; severe comorbidity that would
preclude intensive care treatment following open repair; previous endovascular AAA repair;
women of childbearing potential not taking contraception; pregnant and lactating women
eEVAR anatomical suitability (exclusion criteria): absolute contraindications: no evidence on
aneurysm rupture, juxtarenal aneurysm, neck diameter >32 mm, external iliac artery
diameter >6 mm; relative contraindications: proximal neck length <10 mm, excessive
thrombus in the proximal neck, common iliac artery length <25 mm, heavily calcified iliac
arteries
Interventions eEVAR description: those with a diagnostic CT were transferred directly to operating
theatre, and those without first had a CT scan to determine aortic measurement; performed
in dedicated vascular operating theatre using a Siremobil 2000 image intensifier, with digital
subtraction angiography facilities; most patients heparinised; two-piece aortouniiliac stent
graft made with Gianturco stents with uncovered suprarenal component; occluding device
used in contralateral common iliac artery; after deployment of stent graft, a femoro-femoral
crossover graft was performed
Open repair description: after randomisation to open repair, patients were transferred
directly to the operating theatre, according to local practice; performed transperitoneally
either by midline or transverse incisions; aorta clamped below renal arteries; patients no
heparinised; inlay technique was used and grafts were gelatin-coated polyester
Outcomes Perioperative mortality, defined as 30-day or in-hospital
Notes ‘Patients were deemed suitable for EVAR if, in the opinion of the operating surgeon, they
could perform the repair’; participants recruited September 2002 to December 2004; five
surgeons on unit, required that surgeon and team available had sufficient expertise to offer
EVAR, if not, conventional open repair was offered; unstable patients that might be
disadvantaged by delay incurred by CT scan could, at the surgeon’s discretion, not be
randomised and taken directly for open repair
Risk of bias
Bias Authors’
judgement
Support for judgement
Random sequence generation
(selection bias
Unclear
risk
‘Randomisation was then performed from sealed opaque envelopes kept in the
Accident and Emergency Department’. Unclear how randomisation sequence
was generated
Allocation concealment
(selection bias)
Low risk ‘Randomisation was then performed from sealed opaque envelopes kept in the
Accident and Emergency Department’
Blinding of participants and
personnel (performance bias);
all outcomes
Low risk Study was unblinded, due to nature of intervention but unlikely to influence
outcomes. ‘The surgeons were blinded to the dimensions of patient’s aorta
until randomisation had taken place’ to avoid bias
Blinding of outcome
assessment (detection bias); all
outcomes
Low risk Not possible to blind team regarding allocation group, but unlikely to influence
outcome measures
Incomplete outcome data
(attrition bias); all outcomes
Low risk All patients accounted for; crossover patients accounted for; similar dropout
rates and reasons between treatment groups
Selective reporting (reporting
bias)
Low risk Most of the protocol outlined in the text; all relevant outcomes reported; with
the exception of mortality, outcomes are not well described in the methods
Other bias Unclear
risk
Underpowered study: 32 of the required 100 patients recruited
AAA, abdominal aortic aneurysm; eEVAR, emergency endovascular aneurysm repair; F, female; M, male.
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Table 3 The details of the Amsterdam Acute Aneurysm Trial (AJAX) study
Methods Study type: multicentre, randomised controlled trial, intention-to-treat
Study aim: compare EVAR and open repair in treating RAAA on mortality and
severe complications
Country: The Netherlands
Setting: three large hospital vascular centres in Amsterdam
Participants Number randomised: total n=116 (eEVAR n=57; open repair n=59)
Age (mean years, 95% CI): eEVAR=74.5 (72.3 to 77.5); open repair=74.5 (72.2 to
76.8)
Gender (M/F): eEVAR=49/8; open repair=50/9
Inclusion criteria: male and females over 18 years; clinical diagnosis of RAAA;
aneurysm accompanied by acute haemorrhage outside of the aortic wall of CTA;
suitable for eEVAR and open repair
Exclusion criteria: extension of the aneurysm to juxtarenal or suprarenal aorta;
kidney transplant; horseshoe kidney; allergy to intravenous contrast; connective
tissue disease; severe haemodynamic instability prohibiting CT
eEVAR anatomical suitability requirements: suitable infrarenal anchoring segment,
minimum length of the infrarenal segment of at least 10–15 mm, infrarenal diameter
of 20–32 mm, no obstructing calcifications, tortuosity of thrombosis, suitable iliac
anchoring segment, ipsilateral iliac diameter of 8–18 mm, contralateral iliac diameter
of 10–20 mm, at least one iliac artery should be able to accommodate an endograft
CVD risk factors (n (%)): diabetes (EVAR n=2 (4%), open repair n=1 (2%));
hypertension (EVAR n=13 (23%), open repair n=10 (17%)); smoker (EVAR n=23
(40%), open repair n=20 (34%)); hyperlipidaemia (EVAR n=13 (23%), open repair
n=19 (32%)); renal disease (EVAR n=1 (2%), open repair n=2 (3%)); pulmonary
disease (EVAR n=7 (12%), open repair n=3 (5%)); carotid disease (EVAR n=16
(28%), open repair n=10 (17%)); cardiac disease (EVAR n=16 (28%), open repair
n=14 (24%))Type of RAAA: infrarenal
Interventions eEVAR description: aortouniiliac endograft and contralateral iliac occluding device,
followed by a femoro-femoral crossover bypass graft
Open repair description: midline laparotomy and exclusion of rupture aneurysm by
either polyester tube or bifurcated graft; conducted under general anaesthesia
Outcomes Composite death and severe complications at 30 days after intervention; long-term
mortality rates (6 months after randomisation); length of hospital and ICU stay;
duration of intubation/ventilation; use of blood products; for EVAR, occurrence of
endoleaks
Notes Study period: April 2004 to February 2011; three main trial centres, all other (seven)
regional hospitals transferred participants to one of the trial centres
Risk of bias
Bias Authors’
judgement
Support for judgement
Random sequence generation
(selection bias)
Low risk ‘The randomization sequence was generated by an independent
clinical research unit using ALEA software for randomization in
clinical trials with a 1:1 allocation using random block sizes of 4 or
6, stratified for each participating centre’.
Allocation concealment (selection bias) Low risk ‘Allocation was concealed using sequentially numbered opaque
sealed envelopes’.
Blinding of participants and personnel
(performance bias); all outcomes
Low risk Surgical team not possible to blind, but unlikely to influence
outcomes
Blinding of outcome assessment
(detection bias); all outcomes
Low risk Double database entry; end point adjudication committee blinded;
independent safety committee blinded
Incomplete outcome data (attrition
bias); all outcomes
Low risk All patients accounted for in CONSORT diagram; both treatment
groups had similar dropout rates and reasons
Selective reporting (reporting bias) Unclear risk Although all predescribed outcomes listed in the Reimerink
publication are reported, quality of life and cost-effectiveness as
described in the study protocol, were not included, suggesting
further publications to emerge
Other bias Low risk None
CVD, cardiovascular disease; eEVAR, emergency endovascular aneurysm repair; F, female; ICU, intensive care unit; M, male; RAAA,
ruptured abdominal aortic aneurysm.
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Details about the trial design, characteristics of partici-
pants, diagnosis of RAAA, eEVAR and open repair pro-
cedures were recorded. Data were collected on the
primary outcome short-term mortality (30-day or
in-hospital) and secondary outcomes: aneurysm
exclusion, major and minor short-term complications,
long-term all-cause mortality and long-term complica-
tions, quality of life, and economic analysis. If data were
missing from publications of the included studies,
attempts were made to contact study authors.
Table 4 The details of the Immediate Management of the Patient with Rupture: Open Versus Endovascular (IMPROVE)
study
Methods Study type: multicentre, randomised controlled trial, open label, intention-to-treat
Study aim: to assess whether EVAR vs open repair reduces early mortality for patients with
suspected RAAA
Country: UK and Canada
Setting: 30 hospital vascular units and specialist centres
Participants Number randomised: total n=613 (eEVAR n=316; open repair n=297)
Age (mean years (±SD)): eEVAR=76.7 (7.4); open repair=76.7 (7.8)
Gender (M/F): eEVAR=246/70; open repair=234/63
Inclusion criteria: men and women over the age of 50 years; clinical diagnosis of RAAA or
ruptured aortoiliac aneurysm, made by a senior trial hospital clinician
Exclusion criteria: previous aneurysm repair; rupture of an isolated internal iliac aneurysm,
aortocaval or aortoenteric fistulae; recent anatomical assessment of the aorta; connective
tissue disorder; if intervention was considered futile
eEVAR anatomical suitability requirements: no absolute requirements will be set for the
study, but proximal neck morphology with a diameter exceeding 32 mm or a length less than
10 mm may be considered unfavourable, and iliac artery diameters should be in the range of
8–22 mm
CVD risk factors (n (%)): not given
Type of RAAA: ‘ruptured AAA or ruptured aortoiliac aneurysm’
Interventions eEVAR description: endovascular supracoeliac aortic balloon occlusion will be used to
support less stable patients; most interventions performed with aortouniiliac graft, but some
patients received bifurcated grafts, with subsequent femoro-femoral crossover graft with
contralateral iliac occlusion; control of aorta achieved using local/region anaesthesia, with
general anaesthesia used later in procedure if necessary Open repair description: CT scan is
optional; aneurysms repaired by cross-clamping the proximal aorta and inserting a prosthetic
inlay graft; performed under general anaesthesia
Outcomes 30-day mortality, 24 h and in-hospital mortality, costs, reinterventions at primary admission
time and place of discharge; cost-effectiveness and mortality at 12 months are planned for
future reporting
Notes Participants recruited September 2009 to July 2013; flow diagram shows 623 randomised,
but 10 were excluded after Data Monitoring Committee reviewed participants, 613 used in
analysis; only 275 (87%) of EVAR and 261 (88%) of open repair had confirmed RAAA
Risk of bias
Bias Authors’
judgement
Support for judgement
Random sequence generation
(selection bias)
Low risk ‘And independent contractor provided telephone randomisation, with
computer-generated assignation of patients in a 1:1 ratio, using variable block
size and stratified by centre’.
Allocation concealment
(selection bias)
Low risk ‘And independent contractor provided telephone randomisation, with computer
generated assignation of patients…’
Blinding of participants and
personnel (performance bias);
all outcomes
Low risk Surgical team not possible to blind, but unlikely to influence outcomes
Blinding of outcome
assessment (detection bias);
all outcomes
Low risk Data verification performed centrally at the trial core laboratory, unclear if
blinding, but unlikely to influence outcomes
Incomplete outcome data
(attrition bias); all outcomes
Low risk All patients accounted for, with both treatment groups having similar dropout
rates/reasoning
Selective reporting (reporting
bias)
Unclear risk All predescribed outcomes reported on, but not all appropriate outcomes
reported yet, suggesting further publications to emerge
Other bias Low risk None
CVD, cardiovascular disease; eEVAR, emergency endovascular aneurysm repair; F, female; M, male; RAAA, ruptured abdominal aortic
aneurysm.
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Assessment of risk of bias in included studies
Included studies were evaluated for quality, independ-
ently by two review authors (SAB and RB), using The
Cochrane Collaboration’s tool for assessing risk of bias.36
This tool provides judgements made on the domains of
sequence generation, allocation concealment methods,
blinding, incomplete outcome data, selective outcome
reporting and other relevant biases. Evaluations of low
risk, unclear risk or high risk were given for each of the
six domains for each included study. Any disagreements
between review authors were resolved through discussion.
Measures of treatment effect
Analysis was planned on an intention-to-treat basis, and
therefore all randomised patients from the included
studies were to be included in analysis. The outcomes
that are dichotomous in nature were to be compiled
into meta-analysis and ORs with 95% CIs were to be cal-
culated. For continuous data, meta-analysis would
provide mean differences with SDs.
Assessment of heterogeneity
A test for heterogeneity examines the null hypothesis
that all studies are evaluating the same effect. We
obtained p values comparing the test statistic with a χ2
distribution. A measure (I2) that describes the percent-
age of total variation across studies due to heterogeneity
rather than by chance was included. A value of 0% indi-
cates no observed heterogeneity, and larger values show
increasing heterogeneity.37
Data synthesis
Data extracted independently by two review authors (SAB
and RB) was compiled and entered into RevMan by one
author (RB). Comparisons of data using meta-analyses
were undertaken using ﬁxed-effects models, unless the
test for heterogeneity yielded a value >50%, in which case
a random-effects model was implemented.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis to evaluate the
impact of patients treated with aortouniiliac devices and
those treated with aortobiiliac devices. The Amsterdam
Acute Aneurysm Trial (AJAX) and Hinchliffe trials only
used aortouniiliac devices, while the Immediate
Management of the Patient with Rupture: Open Versus
Endovascular (IMPROVE) used both methods, with a
greater proportion being aortobiiliac.38–48 However, due
to a paucity of information, subgroup analysis was not
possible at this time.
Sensitivity analysis
Although all the participants in the IMPROVE trial had
a clinical diagnoses of RAAA, on start of the interven-
tion, it was found that only 536 (87%) of the 613 rando-
mised participants had, in fact, a ruptured AAA.46 48 Of
the remaining 77 participants, 22 had symptomatic non-
ruptured AAA, or other ﬁnal diagnoses. Sensitivity ana-
lyses were planned to evaluate the effects of this trial on
the outcomes.
RESULTS
A total of 18 new citations were identiﬁed in the search.
Four were considered not relevant as they were reviews,
and two were added to the excluded studies.49 50 One
study, Endovasculaire ou Chirurgie dans les Anevrysmes
aorto-iliaques Rompus (ECAR), ﬁts the inclusion criteria,
but is currently ongoing, with no published data at this
time.51–53 Ten citations, from three studies, were newly
included.38–48 Five prospective comparative studies were
excluded.29 49 50 54 55 The ﬂow of included and excluded
studies is illustrated by means of a PRISMA diagram (ﬁgure
1). The search string results are presented in table 1.
The three included studies had a total of 761 partici-
pants.38–48 All three studies were RCTs comparing
eEVAR to open surgery repair in patients with a clinical
diagnosis of RAAA on outcomes that included mortality
and complications. AJAX and IMPROVE aimed to evalu-
ate longer term mortality and complications, but at the
time of this review, there was no long-term data pub-
lished from the IMPROVE trial. Also, the IMPROVE trial
evaluated cost-effectiveness by comparing cost-per-
patient between the two trial arms. Currently none of
the included studies have evaluated aneurysm exclusion,
minor complications or quality of life.
Figure 2 Short-term mortality
(30-day or in-hospital) of
emergency endovascular
aneurysm repair (eEVAR) versus
open repair.
Figure 3 Myocardial infarction
of emergency endovascular
aneurysm repair (eEVAR) versus
open repair.
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AJAX and IMPROVE were both multicentre studies,
with AJAX taking place in Amsterdam, the Netherlands,
and IMPROVE in the UK, with one study site in Canada.
Hinchliffe et al was a single-centre trial within England.
All included participants had a clinical diagnosis of
RAAA, but in the IMPROVE study only 536 out of the 613
(87%) randomised participants actually had RAAA, the
remaining 77 had symptomatic non-ruptured AAA (22),
no AAA (10), or asymptomatic AAA or another ﬁnal diag-
nosis (45). For the AJAX study, all randomised partici-
pants were considered suitable for both eEVAR and open
repair, which in the Hinchliffe and IMPROVE studies suit-
ability for eEVAR was determined after randomisation. In
the Hinchliffe and AJAX studies, aortouniiliac grafts were
used in the endovascular trial arm, while the IMPROVE
trial used both this and, more predominately, aortobiiliac
grafts. The data derived from the three studies are out-
lined in tables 2–4 with quality of data described.
Five studies were excluded from this review. Three
studies were prospective trials, treating patients present-
ing with RAAA with eEVAR.29 54 55 However, their com-
parison to open repair was made through retrospective,
‘historical controls’ or with open repair cohorts. One
study was a prospective comparison between eEVAR and
open repair in patients with RAAA, but the study was
non-randomised.49 A ﬁnal study was a non-randomised
study of 55 consecutive patients presenting with RAAA.50
A portion of the participants in the study were collected
retrospectively and a portion prospectively.
Allocation (selection bias)
Both the AJAX and IMPROVE studies adequately
reported random sequence generation, but the
Hinchliffe study did not give a description of how their
sequence was produced, and is therefore at unclear risk.
For allocation concealment, all three studies clearly
explained adequate concealment methods.
Blinding (performance bias and detection bias)
Owing to the nature of the intervention, it is not pos-
sible to blind the surgeons and difﬁcult to blind patients
and the research team to the treatment allocation.
However, we determined that a lack of blinding is
unlikely to inﬂuence the outcomes of interest, and all
three have been listed as low risk for performance and
detection bias. Attempts were made to reduce the risk of
bias by the study authors: in the AJAX study, an end
point adjudication committee and independent safety
committee, both blinded to treatment allocation, were
utilised. The Hinchliffe study kept surgeons blinded to
dimensions of the aorta until randomisation was com-
pleted, and the IMPROVE study utilised a trial core
laboratory to centrally verify outcomes.
Incomplete outcome data (attrition bias) and selective
reporting (reporting bias)
All three included studies adequately accounted for all
participants, giving thorough explanation of all dropout
rates and reasons. All three studies were at a low risk of
attrition bias. Both the AJAX and IMPROVE trials are
lacking important outcome data speciﬁed in their proto-
cols, which include quality of life and costs for both
studies, and complications and long-term survival for the
IMPROVE study. It is assumed that these outcomes will
be reported in future publications, but until that data
are reported, the two studies are at an unclear risk of
reporting bias. The Hinchliffe study reported on all out-
comes speciﬁed.
Other potential sources of bias
The AJAX and IMPROVE studies appear to be free of
other sources of bias, but the Hinchliffe study could be
at risk of bias due to an underpowered study population.
In the publication, it was reported that the study
Figure 4 Stroke complication of emergency endovascular aneurysm repair (eEVAR) versus open repair.
Figure 5 Cardiac complication (moderate or severe) of emergency endovascular aneurysm repair (eEVAR) versus open repair.
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required 100 participants to be adequately powered, yet
they only included 32 patients.
EFFECTS OF INTERVENTIONS
Mortality (30-day or in-hospital)
All three studies were included in the meta-analysis for
mortality (30-day or in-hospital). The ﬁxed-effects
model found no clear evidence to support a difference
in mortality between eEVAR and open repair, OR 0.93
(95% CI 0.69 to 1.25; p=0.63; ﬁgure 2). When the
IMPROVE study was removed for sensitivity analysis, due
to randomisation of patients that did not have RAAA,
the OR moved closer to one and the CI became wider
as the IMPROVE study had a larger study population
than the other two included studies, OR 0.98 (95% CI
0.49 to 1.95; p=0.95).
Complications (30-day)
Myocardial infarction
Only the Hinchliffe study reported myocardial infarc-
tion, but only one event was reported so the CI is very
wide, OR 3.62 (95% CI 0.14 to 95.78; ﬁgure 3). As only
one study was included for this outcome, no overall asso-
ciation could be determined, and the wide CI makes any
conclusion spurious.
Stroke
Both the AJAX and Hinchliffe studies reported stroke
events, but with very few events, and opposing ﬁndings,
the ﬁxed-effects model, with a non-signiﬁcant OR has a
very wide CI that is difﬁcult to derive any meaningful
conclusion from (OR 0.71, 95% CI 0.12 to 4.31; p=0.71;
ﬁgure 4).
Cardiac complications (moderate or severe)
Cardiac complications were evaluated in the AJAX and
Hinchliffe studies. The ﬁxed-effects meta-analysis found
a non-signiﬁcant OR, but again with a wide CI (OR 1.12,
95% CI 0.38 to 3.30; p=0.84; ﬁgure 5).
Renal complications (moderate or severe)
The AJAX and Hinchliffe studies reported renal compli-
cations, and the random-effects model used to analyse
the association found no clear difference between the
interventions, OR 0.70 (95% CI 0.09 to 5.24; p=0.73;
ﬁgure 6).
Severe bowel ischaemia
Only a single study evaluated severe bowel ischaemia
(AJAX), which had an OR of 0.39 (95% CI 0.07 to
2.11), but as only one study was included, no overall
association could be determined (ﬁgure 7).
Spinal cord ischaemia
Spinal cord ischaemia was also only evaluated in the
AJAX study, which had only one event. With an OR of
3.16 and a 95% CI of 0.13 to 79.17, very little can cur-
rently be concluded regarding this outcome (ﬁgure 8).
Reoperation
The occurrence of reoperation, speciﬁc to the aneurysm
repair, was reported in two studies (AJAX and
Hinchliffe). The ﬁxed-effects model did not ﬁnd clear
evidence to support a difference between the interven-
tions, OR 0.89 (95% CI 0.39 to 2.01; p=0.78), again with
a rather wide CI (ﬁgure 9).
Amputation
The AJAX trial was the only study to evaluate amputa-
tion, and with the few events, all in the open repair
intervention group, the OR of 0.14 (95% CI 0.01 to
2.78) had a wide CI and no association to be concluded,
as only a single study was included (ﬁgure 10).
Respiratory failure
Respiratory failure was evaluated in the Hinchliffe study,
alone. With only a single event in the eEVAR arm, the
CI was very wide, OR 3.62 (95% CI 0.14 to 95.78) with
no overall association (ﬁgure 11).
Figure 6 Renal complications (moderate or severe) of emergency endovascular aneurysm repair (eEVAR) versus open repair.
Figure 7 Bowel ischaemia of emergency endovascular aneurysm repair (eEVAR) versus open repair.
Badger SA, et al. BMJ Open 2016;6:e008391. doi:10.1136/bmjopen-2015-008391 9
Open Access
Long-term outcomes (6 months)
Long-term outcomes were only evaluated in the AJAX
study. There was no clear evidence to support a differ-
ence between the interventions for mortality at
6 months in the eEVAR arm (OR 0.89, 95% CI 0.40 to
1.98; ﬁgure 12), or long-term reoperation (OR 1.28,
95% CI 0.53 to 3.06; ﬁgure 13). No conclusions could
be drawn from the single study.
Cost per patient (30-day)
Cost per patient was only evaluated in the IMPROVE
study, which found the mean cost slightly less in the
eEVAR treated arm after 30 days, £13 433 compared with
£14 619 in the open repair group. The mean difference
worked out to be £1186, favouring eEVAR, but as both
trial arms had large SDs, the 95% CI was very wide,
spanning £−2996.24 to £624.24. As only a single study
reported on cost, no overall association could be deter-
mined (ﬁgure 14).
Open conversion
As open conversion can only be evaluated in the eEVAR
treatment group, meta-analysis is not an appropriate way
to compare this outcome between the three studies. The
AJAX reported 10 cases of open conversion in the 57
(17.5%) participants randomised to eEVAR. Hinchliffe
had 1 open conversions out of the 15 (6.7%) rando-
mised to eEVAR, and the IMPROVE study only had 4
out of 316 (1.3%) randomised, which is far lower than
the other two trials. This could also be the result of the
13% of randomised participants in the IMPROVE study
that did not have RAAA, but rather 22 participants had
symptomatic non-ruptured AAA, 10 had no AAA and 45
had asymptomatic AAA or other ﬁnal diagnoses and also
84 participants randomised to eEVAR were determined
unsuitable for the procedure and moved to open repair,
but were not considered open conversion.
Table 5 contains perioperative and postoperative
patient characteristics that were not considered as out-
comes in this review, but are of interest when comparing
eEVAR with open repair, and also for comparisons
between the trials. The table addresses time spent
waiting for surgical intervention, time in operating
theatre, blood loss during operation and length of time
spent in hospital. As two studies used median and IQR
and one study reported using mean and SD, the ﬁnd-
ings could not be compared quantitatively, but rather
used for anecdotal analysis.
DISCUSSION
The three studies eligible for inclusion in this review
were of good quality. The evidence gathered was relevant
but there were few data to support an association, and
other outcomes of interest were not acknowledged
within the studies, such as minor complications and
quality of life. Although all potential sources of data were
carefully vetted, it remains possible that relevant data
were not published, or that were not found in the search.
All three included studies did require a clinical diag-
nosis of RAAA for inclusion in the study, yet the
IMPROVE study, on start of intervention, found that 77
(13%) of their included, randomised participants did
not have RAAA; 22 had symptomatic non-ruptured AAA,
10 had no AAA and 45 had asymptomatic AAA or
another ﬁnal diagnosis. The authors of the IMPROVE
trial claimed this method was a more ‘real-world’
approach to the issue. While this may not effect the
overall outcomes, it is of concern. Also, the IMPROVE
trial did not assess eEVAR suitability prior to randomisa-
tion, which resulted in 84 participants randomised to
eEVAR not being suitable for the procedure and trans-
ferred to open repair. Hinchliffe et al also did not select
participants for their suitability for both eEVAR and
open repair prior to randomisation, and one patient
randomised to eEVAR was transferred to open repair.
The AJAX trial evaluated a more selected study popula-
tion of participants suitable for both eEVAR and open
repair. These methodological differences could possibly
alter the applicability of the evidence as the results
could be aimed at different populations.
Figure 8 Spinal cord ischaemia
of emergency endovascular
aneurysm repair (eEVAR) versus
open repair.
Figure 9 Reoperation of emergency endovascular aneurysm repair (eEVAR) versus open repair.
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Figure 10 Amputation after emergency endovascular aneurysm repair (eEVAR) versus open repair.
Figure 11 Respiratory failure of emergency endovascular aneurysm repair (eEVAR) versus open repair.
Figure 14 Cost per patient (30 days) of emergency endovascular aneurysm repair (eEVAR) versus open repair.
Table 5 The perioperative details of the three studies
AJAX (median, IQR) Hinchliffe (median, IQR) IMPROVE (mean, SD)
Time waiting for procedure
EVAR 74 min (39–126) 93 min (±370)
Open repair 45 min (35–70) 73 min (±157)
Time in operating theatre
EVAR 185 min (160–236) 160 min (150–234) 156 min (±100)
Open repair 157 min (136–194) 150 min (141–204) 180 min (±107)
Blood loss during operation
EVAR 500 mL (200–1375) 200 mL (163–450)
Open repair 3500 mL (1000–4600) 2100 mL (1150–3985)
Length of hospital stay
EVAR 9 days (4–21) 10 days (6–28) 9.8 days (±9.0)
Open repair 13 days (5–21) 12 days (4–52) 12.2 days (±10.2)
EVAR, endovascular aneurysm repair.
Figure 13 Reoperation at 6 months for emergency endovascular aneurysm repair (eEVAR) versus open repair.
Figure 12 Mortality at 6 month for emergency endovascular aneurysm repair (eEVAR) versus open repair.
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This is the ﬁrst systematic review, evaluating only
studies that are prospective, RCTs, comparing eEVAR
with open repair in patients with RAAA. There have
been other studies, including several systematic reviews,
that have addressed eEVAR versus open repair in
patients with RAAA, but these have been mostly observa-
tional, non-randomised studies, many of which were
retrospective. These types of studies are more likely
subject to bias, compared with RCTs.
Visser et al56 included 10 observational studies compar-
ing patients who underwent eEVAR or open surgery,
looking at short-term outcomes. A crude random-effects
model for 30-day mortality, comparing eEVAR with open
repair found that when patient haemodynamic condi-
tion at presentation was included in the model, that
both modalities are suitable for treatment of patients
with RAAA, and that eEVAR may possibly have a higher
30-day survival. The crude and adjusted ORs showed a
stronger relationship between lower mortality in the
eEVAR group than our own results for the 30-day mortal-
ity outcome, which showed no difference between the
two interventions. The Visser study also evaluated a com-
posite, systemic complications outcome, which found a
lower point estimate within the eEVAR group, 28%
(95% CI 17% to 48%), compared with open repair, 56%
(95% CI 37% to 85%), indicating fewer complications
within the eEVAR group.56 The present study did not
have sufﬁcient data on complications to compare with
these results, nor was a composite, systemic complica-
tions outcome included.
The Takagi and Umemoto57 meta-analysis included 11
RCTs or risk-adjusted observational studies, with a total
of 42 888 patients. Inclusion criteria required studies to
be RCTs or risk-adjusted observational comparative
studies. This review included 1 RCT and 10 observa-
tional studies. While the present mortality results
showed little difference between eEVAR and open
repair, the Takagi study showed a strong relationship of
lower mortality in the eEVAR arm (p<0.0001).57
Another meta-analysis included 18 studies, of which 11
were retrospective, and 2 of the RCTs in the present
review.58 The review demonstrated a lower mortality and
shorter length of stay in the eEVAR group (p=0.01).
However, the heterogeneity of study designs in the
meta-analysis signiﬁcantly detracts from the quality of
the results and conclusions.
Another review included 41 studies, of which 2 were
RCTs, and the remaining were observational,
population-based studies, with a total of 59 941 partici-
pants.59 The authors found a statistically signiﬁcant
lower mortality for the participants who underwent
eEVAR, compared with open repair, OR 0.56 (95% CI
0.50 to 0.64; p<0.00001). The mortality outcome showed
a strong mortality odds reduction for the eEVAR group
where our study found little difference. Many of the
complications evaluated in the Antoniou study also
showed lower risk in the eEVAR group. The authors also
evaluated cardiac complications, showing a borderline
statistically signiﬁcant risk difference favouring eEVAR
(−0.02, 95% CI −0.03 to 0.00; p=0.05). The ﬁndings of
complication outcomes in our review cannot currently
be compared as there is not enough data to make any
deﬁnitive conclusions.
Owing to a lack of data, this present review, using
only prospective RCTs, was unable to determine super-
iority of either eEVAR or open repair for RAAA.
Previous retrospective studies have suggested a signiﬁ-
cant survival advantage in case–control study designs for
patients undergoing eEVAR. However, the key differ-
ence between eEVAR and an open historical compara-
tive group is the anatomical conﬁguration. Favourable
anatomy to EVAR may preselect patients who ultimately
will do well despite the modality of surgery. So when
only these selected patients are included in a RCT, no
difference is found in outcomes. Based on these ﬁnd-
ings, it would be difﬁcult to justify complex endovascu-
lar repair of juxtarenal or thoracoabdominal aneurysms
in the emergency setting. Caution also needs to be
voiced in transferring a patient with RAAA from a
centre which can provide open repair, to an alternative
centre equipped to provide both open and endovascu-
lar repair, with a consequent delay in treatment. In add-
ition, while volume outcome analysis supports
centralisation, the provision of both modes of RAAA
repair does not.
Further trials to evaluate the role of eEVAR in the
treatment of RAAA are required, addressing all outcome
measures. The evidence from non-randomised studies,
showing reduced mortality in selected patients deemed
suitable for endovascular repair, may raise ethical con-
cerns in relation to randomising these patients to open
repair. It may, therefore, be necessary to stratify the
patients according to anatomical criteria at the time of
CT diagnosis, so that the studies are powered for sub-
groups analysis.
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